Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.

Onkologie - 1 Nov 2008

Li Jian-Yong, Xu Wei, Wu Wei, Zhu Yu, Qiu Hai-Rong, Zhang Run, Zhang Su-Jiang, Qian Si-Xuan

Abstract excerpt

BACKGROUND: Chronic myeloid leukemia (CML) is characterized by the formation of the BCR/ABL fusion gene, as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. This study was to investigate the incidence and prognostic significance of derivative chromosome 9 (der(9)) deletions in CML patients who received hydroxyurea treatment in the chronic phase. PATIENTS AND METHODS: Fluorescence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 9
Share to Gene Deletion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxyurea

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Reproducibility of Results

Share to Risk Assessment

Share to Sensitivity and Specificity

Share to Treatment Outcome

Source

Identifiers

PMID: 19145090
DOI: 10.1159/000160578

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.PMID 19145090Read ↗

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaSemantic proximity Read ↗

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemiaSemantic proximity Read ↗

Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemiaSemantic proximity Read ↗

Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party AnalysisSemantic proximity Read ↗

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemiaSemantic proximity Read ↗

Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.Semantic proximity Read ↗

Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemiaSemantic proximity Read ↗

Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patientsSemantic proximity Read ↗

Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid LeukemiaSemantic proximity Read ↗

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cellsSemantic proximity Read ↗

Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phaseSemantic proximity Read ↗

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.